U.S. Stem Cell, Inc. (USRM) news
U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions has appointed Mark Borman as Chairman of the Board as Dr. William P. Murphy Jr transitions to Chairman Emeritus.
“Mark Borman brings the best of both small-enterprise experience and large-company discipline.. In addition to the valuable knowledge he gained working with entrepreneurs and their startups since 2009, his performa
U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions will take steps to relaunch its veterinary division to tackle animal health innovation.
U.S. Stem Cell’s longstanding animal division, Vetbiologics, has for years provided the Veterinary field with comprehensive regenerative medicine solutions – from training to products and services. Vetbiologics now aims to expand fur
SUNRISE, FL – June. 8th, 2021 – U.S. Stem Cell, Inc. (OTC: USRM), a corporation that has historically focused on the regenerative medicine / cellular therapy industry specializing in physician training and certification and stem cell products in both human and veterinary stem cell processes , has received the results of the Appeal from the United States 11th District Court for the Southern District of Florida.
Since May 9th, 2018, U.S. Stem Cell, as
SUNRISE, FL – Feb 23, 2021 – U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based, and novel regenerative medicine solutions, is pleased to announce the efforts of NorthStar Biotech Group and USRM Board Members to reinvest in U.S. Stem Cell, Inc.
On May 9, 2018, the U.S. Department of Justice, at the request of the U.S. Food and Drug Administration (FDA), filed suit against U.S. Stem Cell, Inc. and others to enjoin
SUNRISE, FL – Jan 19, 2021 – U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based, and novel regenerative medicine solutions, is pleased to announce that oral arguments in the case United States v. U.S. Stem Cell Clinic, LLC, et al., took place on January 13, 2021, before the federal Eleventh Circuit Court of Appeals. The oral argument was held on the Company’s appeal of a judgment denying it the right to prese
U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based, and novel regenerative medicine solutions, is pleased to announce that oral arguments for the company’s court case USA v. U.S. Stem Cell Clinic, et al has been set for the docket beginning January 11, 2021.
Since May 9, 2018, U.S. Stem Cell Inc., as one of the parties named, has been challenged by an injunctive action filed by the U.S. Department of Justice, at the request of the
U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced earnings for the second quarter that ended June 30, 2019. U.S. Stem Cell, Inc posted second-quarter earnings of $1.2M.
While second-quarter earnings lagged, the Company’s results took into account the current regulatory environment. Compared to second quarter of 2018, year-over-year revenue decreased $522k or
U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced earnings for the second quarter that ended June 30, 2019. Correction: U.S. Stem Cell, Inc. posted second-quarter revenues of $1.2M.
While second-quarter earnings lagged, the Company’s results took into account the current regulatory environment. Compared to second quarter of 2018, year-over-year revenue decre
U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced financial results for the first quarter ended March 31, 2019.
For the first time in two years, the Company’s revenue decreased. The drop was 24%, from $1.7M in the first quarter of 2018 to $1.3M in the current quarter.
“ We are working to achieve the
U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced positive financial results for the year ended December 31, 2018.
Consistent with performance for the past two years, revenue continues to increase, up 21% or $1.2m for year-end, 2018 compared to 2017, from $5.5m to $6.7m. Likewise, for the three months ended December 31, 2018, the Com